United States Biosimilar Insulin Market Report 2017

September 2017 | 107 pages | ID: UA9AF30960BEN
QYResearch

Abstracts

In this report, the United States Biosimilar Insulin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Biosimilar Insulin in these regions, from 2012 to 2022 (forecast).

United States Biosimilar Insulin market competition by top manufacturers/players, with Biosimilar Insulin sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Pfizer
• Biogenomics
• Eli Lilly
• Gan&Lee Pharmaceuticals
• Geropharm
• Julphar Gulf Pharmaceutical Industries
• Paras Biopharmaceuticals
• Samsung Bioepis
• Sedico
• Wockhardt
• Teva Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Rapid Acting Insulins
• Short Acting Insulins
• Intermediate Insulins
• Long Lasting Insulins

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biosimilar Insulin for each application, including

• Hospital
• Clinic
• Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Biosimilar Insulin Market Report 2017

1 BIOSIMILAR INSULIN OVERVIEW

1.1 Product Overview and Scope of Biosimilar Insulin
1.2 Classification of Biosimilar Insulin by Product Category
  1.2.1 United States Biosimilar Insulin Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Biosimilar Insulin Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Rapid Acting Insulins
  1.2.4 Short Acting Insulins
  1.2.5 Intermediate Insulins
  1.2.6 Long Lasting Insulins
1.3 United States Biosimilar Insulin Market by Application/End Users
  1.3.1 United States Biosimilar Insulin Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Medical Center
1.4 United States Biosimilar Insulin Market by Region
  1.4.1 United States Biosimilar Insulin Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Biosimilar Insulin Status and Prospect (2012-2022)
  1.4.3 Southwest Biosimilar Insulin Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Biosimilar Insulin Status and Prospect (2012-2022)
  1.4.5 New England Biosimilar Insulin Status and Prospect (2012-2022)
  1.4.6 The South Biosimilar Insulin Status and Prospect (2012-2022)
  1.4.7 The Midwest Biosimilar Insulin Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Biosimilar Insulin (2012-2022)
  1.5.1 United States Biosimilar Insulin Sales and Growth Rate (2012-2022)
  1.5.2 United States Biosimilar Insulin Revenue and Growth Rate (2012-2022)

2 UNITED STATES BIOSIMILAR INSULIN MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Biosimilar Insulin Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Biosimilar Insulin Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Biosimilar Insulin Average Price by Players/Suppliers (2012-2017)
2.4 United States Biosimilar Insulin Market Competitive Situation and Trends
  2.4.1 United States Biosimilar Insulin Market Concentration Rate
  2.4.2 United States Biosimilar Insulin Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Biosimilar Insulin Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES BIOSIMILAR INSULIN SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Biosimilar Insulin Sales and Market Share by Region (2012-2017)
3.2 United States Biosimilar Insulin Revenue and Market Share by Region (2012-2017)
3.3 United States Biosimilar Insulin Price by Region (2012-2017)

4 UNITED STATES BIOSIMILAR INSULIN SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Biosimilar Insulin Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Biosimilar Insulin Revenue and Market Share by Type (2012-2017)
4.3 United States Biosimilar Insulin Price by Type (2012-2017)
4.4 United States Biosimilar Insulin Sales Growth Rate by Type (2012-2017)

5 UNITED STATES BIOSIMILAR INSULIN SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Biosimilar Insulin Sales and Market Share by Application (2012-2017)
5.2 United States Biosimilar Insulin Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES BIOSIMILAR INSULIN PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Pfizer
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Biosimilar Insulin Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Pfizer Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Biogenomics
  6.2.2 Biosimilar Insulin Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Biogenomics Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Eli Lilly
  6.3.2 Biosimilar Insulin Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Eli Lilly Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Gan&Lee Pharmaceuticals
  6.4.2 Biosimilar Insulin Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Gan&Lee Pharmaceuticals Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Geropharm
  6.5.2 Biosimilar Insulin Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Geropharm Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Julphar Gulf Pharmaceutical Industries
  6.6.2 Biosimilar Insulin Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Paras Biopharmaceuticals
  6.7.2 Biosimilar Insulin Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Paras Biopharmaceuticals Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Samsung Bioepis
  6.8.2 Biosimilar Insulin Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Samsung Bioepis Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Sedico
  6.9.2 Biosimilar Insulin Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Sedico Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Wockhardt
  6.10.2 Biosimilar Insulin Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Wockhardt Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Teva Pharmaceuticals

7 BIOSIMILAR INSULIN MANUFACTURING COST ANALYSIS

7.1 Biosimilar Insulin Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Biosimilar Insulin

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Biosimilar Insulin Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Biosimilar Insulin Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES BIOSIMILAR INSULIN MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Biosimilar Insulin Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Biosimilar Insulin Sales Volume Forecast by Type (2017-2022)
11.3 United States Biosimilar Insulin Sales Volume Forecast by Application (2017-2022)
11.4 United States Biosimilar Insulin Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Biosimilar Insulin
Figure United States Biosimilar Insulin Market Size (K Pcs) by Type (2012-2022)
Figure United States Biosimilar Insulin Sales Volume Market Share by Type (Product Category) in 2016
Figure Rapid Acting Insulins Product Picture
Figure Short Acting Insulins Product Picture
Figure Intermediate Insulins Product Picture
Figure Long Lasting Insulins Product Picture
Figure United States Biosimilar Insulin Market Size (K Pcs) by Application (2012-2022)
Figure United States Sales Market Share of Biosimilar Insulin by Application in 2016
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Medical Center Examples
Table Key Downstream Customer in Medical Center
Figure United States Biosimilar Insulin Market Size (Million USD) by Region (2012-2022)
Figure The West Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biosimilar Insulin Sales (K Pcs) and Growth Rate (2012-2022)
Figure United States Biosimilar Insulin Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Biosimilar Insulin Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table United States Biosimilar Insulin Sales (K Pcs) of Key Players/Suppliers (2012-2017)
Table United States Biosimilar Insulin Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biosimilar Insulin Sales Share by Players/Suppliers
Figure 2017 United States Biosimilar Insulin Sales Share by Players/Suppliers
Figure United States Biosimilar Insulin Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Biosimilar Insulin Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Biosimilar Insulin Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Biosimilar Insulin Revenue Share by Players/Suppliers
Figure 2017 United States Biosimilar Insulin Revenue Share by Players/Suppliers
Table United States Market Biosimilar Insulin Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)
Figure United States Market Biosimilar Insulin Average Price (USD/Pcs) of Key Players/Suppliers in 2016
Figure United States Biosimilar Insulin Market Share of Top 3 Players/Suppliers
Figure United States Biosimilar Insulin Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Biosimilar Insulin Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Biosimilar Insulin Product Category
Table United States Biosimilar Insulin Sales (K Pcs) by Region (2012-2017)
Table United States Biosimilar Insulin Sales Share by Region (2012-2017)
Figure United States Biosimilar Insulin Sales Share by Region (2012-2017)
Figure United States Biosimilar Insulin Sales Market Share by Region in 2016
Table United States Biosimilar Insulin Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Biosimilar Insulin Revenue Share by Region (2012-2017)
Figure United States Biosimilar Insulin Revenue Market Share by Region (2012-2017)
Figure United States Biosimilar Insulin Revenue Market Share by Region in 2016
Table United States Biosimilar Insulin Price (USD/Pcs) by Region (2012-2017)
Table United States Biosimilar Insulin Sales (K Pcs) by Type (2012-2017)
Table United States Biosimilar Insulin Sales Share by Type (2012-2017)
Figure United States Biosimilar Insulin Sales Share by Type (2012-2017)
Figure United States Biosimilar Insulin Sales Market Share by Type in 2016
Table United States Biosimilar Insulin Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Biosimilar Insulin Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Biosimilar Insulin by Type (2012-2017)
Figure Revenue Market Share of Biosimilar Insulin by Type in 2016
Table United States Biosimilar Insulin Price (USD/Pcs) by Types (2012-2017)
Figure United States Biosimilar Insulin Sales Growth Rate by Type (2012-2017)
Table United States Biosimilar Insulin Sales (K Pcs) by Application (2012-2017)
Table United States Biosimilar Insulin Sales Market Share by Application (2012-2017)
Figure United States Biosimilar Insulin Sales Market Share by Application (2012-2017)
Figure United States Biosimilar Insulin Sales Market Share by Application in 2016
Table United States Biosimilar Insulin Sales Growth Rate by Application (2012-2017)
Figure United States Biosimilar Insulin Sales Growth Rate by Application (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Pfizer Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Pfizer Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Biogenomics Basic Information List
Table Biogenomics Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Biogenomics Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Biogenomics Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Biogenomics Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Eli Lilly Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Eli Lilly Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Eli Lilly Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Gan&Lee Pharmaceuticals Basic Information List
Table Gan&Lee Pharmaceuticals Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Gan&Lee Pharmaceuticals Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Gan&Lee Pharmaceuticals Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Gan&Lee Pharmaceuticals Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Geropharm Basic Information List
Table Geropharm Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Geropharm Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Geropharm Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Geropharm Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Julphar Gulf Pharmaceutical Industries Basic Information List
Table Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Julphar Gulf Pharmaceutical Industries Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Paras Biopharmaceuticals Basic Information List
Table Paras Biopharmaceuticals Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Paras Biopharmaceuticals Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Paras Biopharmaceuticals Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Paras Biopharmaceuticals Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Samsung Bioepis Basic Information List
Table Samsung Bioepis Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Samsung Bioepis Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Samsung Bioepis Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Samsung Bioepis Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Sedico Basic Information List
Table Sedico Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Sedico Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Sedico Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Sedico Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Wockhardt Basic Information List
Table Wockhardt Biosimilar Insulin Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Wockhardt Biosimilar Insulin Sales Growth Rate (2012-2017)
Figure Wockhardt Biosimilar Insulin Sales Market Share in United States (2012-2017)
Figure Wockhardt Biosimilar Insulin Revenue Market Share in United States (2012-2017)
Table Teva Pharmaceuticals Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Biosimilar Insulin
Figure Manufacturing Process Analysis of Biosimilar Insulin
Figure Biosimilar Insulin Industrial Chain Analysis
Table Raw Materials Sources of Biosimilar Insulin Major Players/Suppliers in 2016
Table Major Buyers of Biosimilar Insulin
Table Distributors/Traders List
Figure United States Biosimilar Insulin Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)
Figure United States Biosimilar Insulin Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Biosimilar Insulin Price (USD/Pcs) Trend Forecast (2017-2022)
Table United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Type (2017-2022)
Figure United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Type in 2022
Table United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Application (2017-2022)
Figure United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Application in 2022
Table United States Biosimilar Insulin Sales Volume (K Pcs) Forecast by Region (2017-2022)
Table United States Biosimilar Insulin Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biosimilar Insulin Sales Volume Share Forecast by Region (2017-2022)
Figure United States Biosimilar Insulin Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources